Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Protesters holding a banner during the 'Free the Vaccine' protest. Alamy Stock Photo

Breakthrough on Covid vaccine intellectual rights reached by EU, US, India and South Africa

The EU has climbed down on its position in order to help get the whole world equal access to vaccines.

THE WORLD TRADE Organization chief hailed a breakthrough between the EU, the US, India and South Africa on waiving intellectual property rights on Covid-19 vaccines.

EU member states still need to agree to the compromise, which has not been officially revealed.

Ngozi Okonjo-Iweala said the compromise was a big step forward in a bid to end the logjam at the global trade body.

However, she cautioned that some of the details on waiving WTO rules on Trade-Related Aspects of Intellectual Property Rights (TRIPS) still needed to be fleshed out – and it would need the backing of all WTO members to come into force.

“This is a major step forward and this compromise is the result of many long and difficult hours of negotiations,” Okonjo-Iweala said.

“But we are not there yet. We have more work to do to ensure that we have the support of the entire WTO membership.”

The exact compromise that has been reached has not been officially confirmed, but leaked reports from Reuters and Politico indicate that the length of the waiver would be between 3-5 years, and that it would apply to developing countries that have exported less than 10% of the world’s coronavirus vaccine doses last year.

Jim Clarken, CEO of Oxfam Ireland said that the compromise “ignores other intellectual property barriers like trade secrets which stand in the way of vaccine manufacturers”.

And by focusing only on vaccines and kicking the issue of COVID-19 treatments into the long grass, it will leave life-saving treatments out of reach for millions.

Since October 2020, South Africa and India have called for IP rights to be temporarily lifted for coronavirus vaccines during the pandemic in order to boost production and address the gaping inequality in access between rich and poor nations.

However the idea has met with fierce opposition from pharmaceutical giants and many of their host countries.

They have argued that patents are not the main roadblocks to scaling up production and warn the move could hamper innovation.

Okonjo-Iweala’s statement came hours after Adam Hodge, spokesman for the US Trade Representative Katherine Tai, announced that lengthy talks had resulted in a “compromise outcome that offers the most promising path toward achieving a concrete and meaningful” result.

“No agreement on text has been reached and we are in the process of consulting on the outcome,” he added.

‘Wrong solution’: pharma lobby

Okonjo-Iweala stressed that internal domestic consultations were going on in the four parties to the compromise agreement, and some points still needed smoothing out.

But the former Nigerian finance minister said work would start immediately to widen the discussion to all 164 WTO members.

Switzerland, home to several major pharmaceutical companies, has notably repeatedly voiced its unwillingness to budge.

The International Federation of Pharmaceutical Manufacturers and Associations big pharma lobby group slammed the compromise, saying that weakening patents when supply constraints had eased was a mistake.

The IFPMA said 12 billion vaccine doses had been produced within a year of the first jab being authorised, and the industry was now pumping out more than a billion doses per month.

“The challenge now is how to get the vaccines into the arms of people who need them, rather than vaccine supply,” the group said.

“The TRIPS waiver is not only the wrong solution, it is also an outdated proposal, that has been overtaken by events.”

The IFPMA said the waiver was “unnecessary and irrelevant” and could undermine innovation in response to future pandemics.

 EU ‘climbdown’

Max Lawson, co-chair of the People’s Vaccine Alliance coalition campaigning for wider access to Covid vaccines, said the TRIPS waiver proposals did not go far enough.

“After almost 18 months of stalling and millions of deaths, the EU has climbed down and finally admitted that intellectual property rules and pharmaceutical monopolies are a barrier to vaccinating the world,” he said.

But Lawson said the proposal was a half-measure and did not address IP rights on Covid-19 treatments.

“Every barrier to accessing these crucial vaccines and treatments must be cleared away,” he said.

© AFP 2022

Author
View 3 comments
Close
3 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel

     
    JournalTv
    News in 60 seconds